- Melanie Goshgarian of National Patient Network and me at FDA Is It Broken? #STATHUBweek Thanks @statnews @NC4HR
- STAT's Ed Silverman of @pharmalot is leading a panel right now on the FDA's drug approval process #STATHubweekhttp://bit.ly/2cyRrLG
- "approvals don't come from a black box" a panel featuring the people behind #FDA approvals #STATHUBweek
- Packed house at @ragoninstitute for @statnews panel on the FDA and the Drug Approval Process. Smart, engaged audience#HUBweek #STATHUBweek
- Panel on whether FDA approval process is broken with#stathubweek and industry expertshttps://twitter.com/comptech_bio/status/780838529186222080 …
- At #STATHubweek panel on #FDA drug approval process, discussion immediately focuses on approval of Sarepta's #DMDdrug. HT @NC4HR
- Diana Zuckerman "I am one of FDA's biggest fans, and one of its strongest critics." Go for scientific evidence. #STATHUBweek
- Packed house @ragoninstitute for #STATHUBweekconversation on FDA drug approval process #HUBweek@statnews @TakedaOncology
- Diana Zuckerman of @NC4HR: FDA needs to listen to patients on benefits AND harms of drugs AND devices. And scientific research #STATHUBweek
- "We've seen remarkable progress (in the drug approval process) in the last five years" - John Crowley #HUBweek#STATHUBweek @pharmalot
- John Crowley on flexibility of balancing benefits and risk vs. strict safety and efficacy at FDA. #STATHUBweek
- Ira Loss Investor Perspective on FDA drug approval process. renewal of Rx Drug Reg Act is pro-patient. #STATHUBweek
- "Patient perspectives shouldn't replace really good scientific data" - Diane Zuckerman, PhD #STATHUBweek #HUBweek@pharmalot
- "[The FDA's] not perfect, but they know what they're doing." - Ira Loss of Washington Analysis #STATHUBweek
- "It's critical to have patient perspectives early on in the (drug approval) process" - John Crowley #STATHUBweek #HUBweek@pharmalot
- This #STATHUBweek FDA panel moderated by @pharmalot is trying to be a $SRPT bash party, but failing badly.
- More about the Sarepta drug approval pathway:https://www.statnews.com/pharmalot/2016/09/19/sarepta-fda-duchenne-behind-the-decision/ … via @statnews #pharmalot#stathubweek #raredisease
- $FOLD Crowley: Last thing I’d do is go to my board, use $SRPTas ex. of how to get drug approved. It was 1-off FDA exception.#STATHUBweek
- Diana Zuckerman of @NC4HR stresses the rising price of premiums and co-pays associated with $SRPT Duchenne's drug price tag #STATHUBweek
- "Patients are empowered today as never before," says FDA's Dr. Rich
Moscicki in discussion about state of FDA drug approvals.#stathubweek - Diana Zuckerman talks about why a #DMD drug was approved: vocal patients vs. medical opinion #STATHUBweek
- "We do need science in order to make a move. We will not approve drugs by acclamation." - Richard Moscicki of@US_FDA #STATHUBweek
- Richard Mosicki, FDA’a Deputy Center Director for Science Ops, says eteplirsen approval was "science-based decision.” $SRPT#STATHUBweek
- "We are very interested in patient perspectives...patients are empowered today as never before" -Richard Moscicki, MD, FDA CDER #STATHUBweek
- "#FDA + the #Drug Approval Process: is it Broken?"@ragoninstitute @kendallnow #Cambridge #MedProdDev#STATHUBweek Thanks @statnews #Takeda
- Richard Moscicki MD on the FDA CDER new Sentinel project and parallel UID effort in CDRH. #STATHUBweek
- Should FDA consider advocacy groups in approval process? "Patients are more empowered than ever before."@patientslikeme #STATHUBweek
- Thank you to @CVSHealth, @TakedaOncology, and Precision Medicine Group for sponsoring today's #STATHUBweek panels!
- @TakedaOncology @HUBweek Loved building, writing, folding and sending that crane! Great message and concept.
Like
Share
No comments:
Post a Comment